Castle Biosciences Inc (CSTL)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $1.04B
Last updated: Nov 17, 2026 at 11:05 AM ET
Castle Biosciences Inc (CSTL) Financials: Revenue, Profit and Cash Flow
Castle Biosciences reported revenue of $344.23M for the fiscal year ended Dec 31, 2025, up 3.7% from the year before. That year, net income was -$24.16M with a net margin of -7.0%, operating cash flow was $64.35M and free cash flow was $28.33M. The quarter ended Sep 30, 2026 had revenue of $102.89M and net income of -$4.10M.
Revenue and Margins
The operating margin was -12.4% in the fiscal year ended Dec 2025. Over the 8 years to Dec 2025, revenue grew from $13.75M, a compound annual rate of 49.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $344.23M | +3.7% | 79.4% | -12.4% | -7.0% |
| Dec 2024 | $332.07M | +51.1% | 81.9% | 2.6% | 5.5% |
| Dec 2023 | $219.79M | +60.4% | 79.5% | -30.9% | -26.1% |
| Dec 2022 | $137.04M | +45.7% | 76.6% | -53.2% | -49.0% |
| Dec 2021 | $94.08M | +50.2% | 83.2% | -42.6% | -33.3% |
| Dec 2020 | $62.65M | +20.8% | 84.5% | -10.4% | -16.4% |
| Dec 2019 | $51.87M | +127.6% | 85.9% | 14.1% | 10.2% |
| Dec 2018 | $22.79M | +65.7% | 76.8% | -16.8% | -27.9% |
| Dec 2017 | $13.75M | N/A | 64.2% | -79.2% | -89.9% |
Income Statement
In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $344.23M | $332.07M | $219.79M | $137.04M | $94.08M | $62.65M | $51.87M | $22.79M | $13.75M |
| Cost of revenue | $71.03M | $60.20M | $44.98M | $32.01M | $15.82M | $9.69M | $7.31M | $5.30M | $4.92M |
| Gross profit | $273.20M | $271.86M | $174.81M | $105.03M | $78.26M | $52.96M | $44.55M | $17.49M | $8.83M |
| Research and development | $51.85M | $52.04M | $53.62M | $44.90M | $29.65M | $13.26M | $7.38M | $4.85M | $4.47M |
| Operating income | -$42.81M | $8.67M | -$67.98M | -$72.86M | -$40.08M | -$6.54M | $7.33M | -$3.84M | -$10.90M |
| Net income | -$24.16M | $18.25M | -$57.47M | -$67.14M | -$31.29M | -$10.28M | $5.28M | -$6.37M | -$12.37M |
| EBITDA | -$6.11M | $17.98M | -$61.14M | -$63.68M | -$36.67M | -$5.23M | N/A | -$3.76M | -$10.40M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $102.89M | $103.55M | $83.68M | $87.01M | $83.04M | $86.19M | $87.99M | $86.31M | $85.78M | $87.00M | $72.97M | $66.12M |
| Gross profit | $78.97M | $79.85M | $63.15M | $68.69M | $64.34M | $68.56M | $71.61M | $70.13M | $70.17M | $72.48M | $59.08M | $53.70M |
| Operating income | -$2.73M | -$3.07M | -$18.41M | -$3.83M | -$6.80M | -$4.25M | -$27.93M | $4.05M | $5.08M | $5.01M | -$5.47M | -$5.66M |
| Net income | -$4.10M | -$2.06M | -$14.52M | -$2.33M | -$501.00K | $4.52M | -$25.85M | $9.59M | $2.27M | $8.92M | -$2.53M | -$2.58M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $10.06M by $106.67M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | $578.56M | $531.24M | $453.34M | $447.33M | $462.57M | $439.33M | $119.75M | $22.40M | $9.82M |
| Current assets | $361.10M | $360.15M | $295.63M | $292.29M | $353.74M | $429.59M | $116.68M | $18.13M | $6.68M |
| Cash and equivalents | $116.73M | $119.71M | $98.84M | $122.95M | $329.63M | $409.85M | $98.84M | $4.48M | $1.21M |
| Total liabilities | $107.68M | $75.40M | $62.07M | $48.18M | $50.83M | $23.64M | $34.63M | $32.47M | $24.09M |
| Short-term debt | $417.00K | $278.00K | $0 | $1.78M | $1.18M | $5.83M | $5.83M | $0 | $1.00M |
| Long-term debt | $9.64M | $9.74M | $0 | N/A | N/A | N/A | $19.29M | $24.50M | $17.60M |
| Shareholder equity | $470.87M | $455.83M | $391.27M | $399.15M | $411.74M | $415.69M | $85.11M | -$56.57M | -$14.27M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $579.41M | $561.18M | $547.80M | $578.56M | $562.79M | $544.73M | $501.71M | $531.24M | $514.57M | $487.31M | $458.51M | $453.34M |
| Total liabilities | $100.96M | $91.15M | $86.39M | $107.68M | $95.74M | $89.35M | $61.41M | $75.40M | $73.51M | $63.42M | $56.05M | $62.07M |
| Cash and equivalents | $77.99M | $62.12M | $63.76M | $116.73M | $85.56M | $82.23M | $89.69M | $119.71M | $94.96M | $85.57M | $82.95M | $98.84M |
| Shareholder equity | $478.44M | $470.03M | $461.42M | $470.87M | $467.05M | $455.38M | $440.31M | $455.83M | $441.06M | $423.89M | $402.46M | $391.27M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 44.0% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $64.35M | $64.87M | -$5.63M | -$41.66M | -$18.98M | $9.87M | $7.01M | -$12.29M | -$12.23M |
| Capital expenditures | $36.02M | $28.33M | $13.62M | $5.63M | $3.48M | $4.75M | $937.00K | $277.04K | $494.85K |
| Free cash flow | $28.33M | $36.54M | -$19.25M | -$47.29M | -$22.47M | $5.11M | $6.08M | -$12.57M | -$12.73M |
| Dividends paid | N/A | N/A | N/A | $1.69M | $3.12M | N/A | N/A | $0 | $0 |
| Share repurchases | N/A | N/A | N/A | N/A | $336.00K | $0 | N/A | N/A | N/A |
| Investing cash flow | -$60.37M | -$50.14M | -$16.18M | -$166.54M | -$66.66M | -$4.75M | -$937.00K | -$277.04K | -$494.85K |
| Financing cash flow | -$6.96M | $6.14M | -$2.30M | $1.51M | $5.42M | $305.89M | $88.29M | $15.84M | $8.87M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $19.74M | $15.20M | -$22.13M | $26.93M | $22.63M | $20.82M | -$6.04M | $24.36M | $23.34M | $24.00M | -$6.83M | $18.59M |
| Capital expenditures | $7.49M | $8.65M | $12.46M | $7.18M | $14.83M | $9.26M | $4.74M | $7.57M | $6.38M | $5.23M | $9.15M | $3.79M |
| Free cash flow | $12.25M | $6.55M | -$34.58M | $19.75M | $7.80M | $11.56M | -$10.78M | $16.80M | $16.96M | $18.77M | -$15.99M | $14.79M |
Frequently Asked Questions About CSTL
What is Castle Biosciences' annual revenue?
Castle Biosciences reported revenue of $344.23M for the fiscal year ended Dec 31, 2025.
How fast is Castle Biosciences' revenue growing?
Revenue was up 3.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 35.9%.
Is Castle Biosciences profitable?
No. Castle Biosciences reported net income of -$24.16M for the fiscal year ended Dec 31, 2025, with a net margin of -7.0%.
How much free cash flow does CSTL generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $64.35M minus capital expenditures of $36.02M produced free cash flow of $28.33M.
How much debt does Castle Biosciences have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $9.64M, short-term debt of $417.00K and cash and equivalents of $116.73M.
CSTL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts